SCHEMBL19616692

SCHEMBL19616692

FC(F)(F)c1ccc2[nH]nc(C3CCCCO3)c2c1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19616876 0.81 PRKAB2 (0.32) —
SCHEMBL19616582 0.81 MAPK8 (0.30) —
SCHEMBL19616539 0.79 CHUK (0.36) —
SCHEMBL19616623 0.79 MAPK8 (0.33) —
SCHEMBL14721720 0.72 PRKAG1 (0.33) —
SCHEMBL31586483 0.71 GAA (0.38) —
SCHEMBL3402451 0.71 GAA (0.44) —
SCHEMBL31162538 0.68 PDE10A (0.33) —
SCHEMBL31190772 0.68 PIM1 (0.33) —
SCHEMBL15740705 0.68 PIM1 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3908283-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2021-11-17 — — EP disclosed
EP-3844151-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2021-07-07 — — EP disclosed
EP-3710439-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-09-23 — — EP disclosed
WO-2020146613-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-07-16 — — WO disclosed
WO-2020047192-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-03-05 — — WO disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 — — EP disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed
Send feedback